heterocyclic organobismuth(III) compound targets tubulin to induce G 2/M arrest in hela cells

Journal of Pharmacological Sciences

Volumn 109, Issue 4, 2009, Pages 573-582

  Iuchi, Katsuya ^a   Akagi, Kiwamu ^b   Yagura, Tatsuo ^a  

^a KWANSEI GAKUIN UNIVERSITY   (Japan)

^b SAITAMA CANCER CENTER   (Japan)

Author keywords

Anticancer; Bismuth; Cell death; Mitotic arrest; Tubulin

Indexed keywords

ANTINEOPLASTIC AGENT; BICHLORODIBENZO[C,F][1,5]THIABISMOCINE; BISMUTH DERIVATIVE; COLCHICINE; CYCLIN B1; NOCODAZOLE; TUBULIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONCENTRATION (PARAMETERS); DRUG INHIBITION; DRUG TARGETING; FEMALE; FLOW CYTOMETRY; HELA CELL; HUMAN; HUMAN CELL; MICROTUBULE; POLYMERIZATION; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

EID: 66249091952     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09020FP     Document Type: Article

References (47)

1. Kotani T, Nagai D, Asahi K, Suzuki H, Yamao F, Kataoka N, et al. Antibacterial properties of some cyclic organobismuth(III) compounds. Antimicrob Agents Chemother. 2005;49:2729-2734.
2. Iuchi K, Hatano Y, Yagura T. Heterocyclic organobismuth(III) induces apoptosis of human promyelocytic leukemic cells through activation of caspases and mitochondrial perturbation. Biochem Pharmacol. 2008;76:974-986.
3. Suzuki H, Matano Y. Organobismuth chemistry. London: Elsevier Science; 2001.
4. Yagura T. Biological activity of organobismuth compounds. Res Adv Antimicrobial Chemother. 2006;6:19-32.
5. Murafuji T, Miyoshi Y, Ishibashi M, Mustafizur Rahman AF, Sugihara Y, Miyakawa I, et al. Antifungal activity of organobismuth compounds against the yeast Saccharomyces cerevisiae: structure-activity relationship. J Inorg Biochem. 2004;98:547-552.
6. Desoize B. Metals and metal compounds in cancer treatment. Anticancer Res. 2004;24:1529-1544.
7. Köpf-Maier P, Klapötke T. Antitumor activity of some organometallic bismuth(III)thiolates. Inorg Chim Acta. 1988;152:49-52.
8. Hadfield JA, Ducki S, Hirst N, McGown AT. Tubulin and microtubules as targets for anticancer drugs. Prog Cell Cycle Res. 2003;5:309-325.
9. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253-265.
10. Chou IN. Distinct cytoskeletal injuries induced by As, Cd, Co, Cr, and Ni compounds. Biomed Environ Sci. 1989;2:358-365.
11. Zhang P, Wang SY, Hu XH. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol. 1996;17:58-61.
12. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89:3354-3360.
13. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998;339:1341-1348.
14. List A, Beran M, DiPersio J, Slack J, Vey N, Rosenfeld CS, et al. Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia. 2003;17:1499-1507.
15. Gazitt Y, Akay C. Arsenic trioxide: an anti cancer missile with multiple warheads. Hematology. 2005;10:205-213.
16. Li YM, Broome JD. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res. 1999;59:776-780.
17. Park JW, Choi YJ, Jang MA, Baek SH, Lim JH, Passaniti T, et al. Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells. Biochem Biophys Res Commun. 2001;286:726-734.
18. Ling YH, Jiang JD, Holland JF, Perez-Soler R. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol Pharmacol. 2002;62:529-538.
19. Cai X, Yu Y, Huang Y, Zhang L, Jia PM, Zhao Q, et al. Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells. Leukemia. 2003;17:1333-1337.
20. Yih LH, Tseng YY, Wu YC, Lee TC. Induction of centrosome amplification during arsenite-induced mitotic arrest in CGL-2 cells. Cancer Res. 2006;66:2098-2106.
21. Huang SC, Lee TC. Arsenite inhibits mitotic division and perturbs spindle dynamics in HeLa S3 cells. Carcinogenesis. 1998;19:889-896.
22. Carre M, Carles G, Andre N, Douillard S, Ciccolini J, Briand C, et al. Involvement of microtubules and mitochondria in the antagonism of arsenic trioxide on paclitaxel-induced apoptosis. Biochem Pharmacol. 2002;63:1831-1842.
23. Goering PL, Aposhian HV, Mass MJ, Cebrian M, Beck BD, Waalkes MP. The enigma of arsenic carcinogenesis: role of metabolism. Toxicol Sci. 1999;49:5-14.
24. Doi K, Noma S, Yamao F, Goko H, Yagura T. Expression of Golgi Membrane Protein p138 is Cell Cycle-independent and Dissociated from Centrosome Duplication. Cell Struct Funct. 2002;27:117-125.
25. Yamauchi T, Higashiura M, Yagura T. Novel monoclonal antibody mAb G3A5 recognizes 138-kDa glycoprotein localized on the Golgi membrane. Cell Struct Funct. 1992;17:213-222.
26. Blagosklonny MV, Schulte TW, Nguyen P, Mimnaugh EG, Trepel J, Neckers L. Taxol induction of p21WAF1 and p53 requires c-raf-1. Cancer Res. 1995;55:20:4623-4626.
27. Roychowdhury M, Sarkar N, Manna T, Bhattacharyya S, Sarkar T, Basusarkar P, et al. Sulfhydryls of tubulin. A probe to detect conformational changes of tubulin. Eur J Biochem. 2000;267: 3469-3476.
28. Bhattacharyya B, Wolff J. Promotion of fluorescence upon binding of colchicine to tubulin. Proc Natl Acad Sci U S A. 1974;71:2627-2631.
29. Sasaki J, Ramesh R, Chada S, Gomyo Y, Roth JA, Mukhopadhyay T. The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Mol Cancer Ther. 2002;1: 1201-1209.
30. Tahir SK, Han EK, Credo B, Jae HS, Pietenpol JA, Scatena CD, et al. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. Cancer Res. 2001;61:5480-5485.
31. McCollum G, Keng PC, States JC, McCabe MJ Jr. Arsenite delays progression through each cell cycle phase and induces apoptosis following G2/M arrest in U937 myeloid leukemia cells. J Pharmacol Exp Ther. 2005;313:877-887.
32. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 1996;56:816-825.
33. Thyberg J, Moskalewski S. Microtubules and the organization of the Golgi complex. Exp Cell Res. 1985;159:1-16.
34. Jordan MA, Thrower D, Wilson L. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res. 1991;51: 2212-2222.
35. Cleveland DW, Lopata MA, Sherline P, Kirschner MW. Unpolymerized tubulin modulates the level of tubulin mRNAs. Cell. 1981;25:537-546.
36. Binet F, Cavalli H, Moisan E, Girard D. Arsenic trioxide (AT) is a novel human neutrophil pro-apoptotic agent: effects of catalase on AT-induced apoptosis, degradation of cytoskeletal proteins and de novo protein synthesis. Br J Haematol. 2006;132:349-358.
37. Kuriyama R, Sakai H. Role of tubulin-SH groups in polymerization to microtubules. Functional-SH groups in tubulin for polymerization. J Biochem. 1974;76:651-654.
38. Basusarkar P, Chandra S, Bhattacharyya B. The colchicinebinding and pyrene-excimer-formation activities of tubulin involve a common cysteine residue in the beta subunit. Eur J Biochem. 1997;244:378-383.
39. Bai R, Pei XF, Boye O, Getahun Z, Grover S, Bekisz J, et al. Identification of cysteine 354 of beta-tubulin as part of the binding site for the A ring of colchicine. J Biol Chem. 1996;271:12639-12645.
40. Masuda A, Maeno K, Nakagawa T, Saito H, Takahashi T. Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers. Am J Pathol. 2003;163:1109-1116.
41. Greene LM, Campiani G, Lawler M, Williams DC, Zisterer DM. BubR1 is required for a sustained mitotic spindle checkpoint arrest in human cancer cells treated with tubulin-targeting pyrrolo-1,5-benzoxazepines. Mol Pharmacol. 2008;73:419-430.
42. Carre M, Andre N, Carles G, Borghi H, Brichese L, Briand C, et al. Tubulin is an inherent component of mitochondrial membranes that interacts with the voltage-dependent anion channel. J Biol Chem. 2002;277:33664-33669.
43. Blajeski AL, Phan VA, Kottke TJ, Kaufmann SH. G(1) and G(2) cell-cycle arrest following microtubule depolymerization in human breast cancer cells. J Clin Invest. 2002;110:91-99.
44. Han YH, Kim SZ, Kim SH, Park WH. Induction of apoptosis in arsenic trioxide-treated lung cancer A549 cells by buthionine sulfoximine. Mol Cells. 2008;26:158-164.
45. Han YH, Kim SZ, Kim SH, Park WH. Arsenic trioxide inhibits the growth of Calu-6 cells via inducing a G2 arrest of the cell cycle and apoptosis accompanied with the depletion of GSH. Cancer Lett. 2008;270:40-55.
46. Li W, Chou IN. Effects of sodium arsenite on the cytoskeleton and cellular glutathione levels in cultured cells. Toxicol Appl Pharmacol. 1992;114:132-139.
47. Hei TK, Liu SX, Waldren C. Mutagenicity of arsenic in mammalian cells: role of reactive oxygen species. Proc Natl Acad Sci U S A. 1998;95:8103-8107.